key: cord-0954685-ykg0fh5q
authors: Hunain, Reem; Uday, Utkarsha; Rackimuthu, Sudhan; Nawaz, Faisal A.; Narain, Kapil; Essar, Mohammad Yasir; Rehman, Majeeb ur; Ahmad, Shoaib; Butt, Ayesha
title: Effects of SARS-CoV-2 vaccination on blood donation and blood banks in India
date: 2022-05-11
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103772
sha: 4e145090dc7da51065f0653d7fe50b976170362d
doc_id: 954685
cord_uid: ykg0fh5q

India, the second most populous country in the world, started its mass vaccination campaign on January 16th 2021. With the aim to vaccinate 1.3 billion people, this vaccination programme was dubbed as the world's largest vaccination drive. However, with depleted blood stores due to the COVID-19 pandemic and lockdown leading to reduced blood camps, the superposed regulations on blood donation deferral poses an impending risk of depletion of blood and its products. This will lead to the inability in meeting unpredictable patterns of demand in blood requirement post-pandemic. Hence to prevent avoidable risks of blood shortage in surgeries and lifesaving procedures, a secure storage system should be ensured.

cases exceeding two hundred thousand on 14th of April 2021. 1 Global analysis of herd immunity in Coronavirus disease 2019 (COVID-19) has shown the urgent need for COVID-19 vaccination efforts in order to curb the pandemic. 2 On January 16, 2021, India began the world's largest vaccination programme for COVID-19, prioritizing the healthcare and frontline workers, followed by geriatric population age and 45 to 59 years aged peoplewith comorbidities. 3 The National Blood Transfusion Council (NBTC) of India issued guidelines on 5 th March, 2021, deferring SARS-CoV-2 vaccinated citizens from donating blood for 28 days post vaccination. 4 This meant deferral for 56 days for Covaxin and 90 days for Covishield, after the first jab, which led to a widespread concern regarding the blood donationcamps and availability of blood components. Hence, donation of blood before getting vaccinated was widely recommended. The directorate general of health services(DGHS), on 5 th May, 2021, reducedthis period to14 days post vaccination and 15 days after a negative reverse transcription polymerase chain reaction (RTPCR) for According to the NBTC, there are 2023 blood banks in India which receive 78% blood from voluntary donors. The land of 1.2 billion peopleneeds 12 million units of blood annually but hardly collects 9 million which is a 25% deficit during non-COVID times, as estimated by the ministry of health and family welfare (MoHFW).However, this year's situation was further worsened due to skyrocketing COVID-19 cases, which have led to a substantial reduction by 50% in the number and scale of blood donation camps organised. 5 Vaccination for the 18 to 45 age group, which comprises the majority of blood donors, can cause massive disruption in the blood donation system in India. Furthermore, nationwide lockdown, fear of transmission of SARS-CoV-2 virus via blood, less demand and hence less supply due to reduced number of elective surgeries and employee absenteeism due to isolation add to probable causes.

Limited shelf life of 35-49 days for blood and blood components has also led to increased rates of discarded unused blood products due to expiry. 6 This deficit in blood donation stores could potentially be further exacerbated by the mass vaccination starting for 18 to 44-year age groups. Individuals who receive live vaccines are usually deferred temporarily from donating blood due to potential risk for transferring the infection through blood and J o u r n a l P r e -p r o o f blood products. 7 Extensive literature searches failto identify any evidence of transmission via transfusion of blood or blood components and no cases have been reported. 8 On the other hand, the pandemic has had a negative impact on blood supplies through reduced blood donation and reduced availability of appropriate collection facilities because of operational disruptions. 9 International regulatory bodies like Food and Drug Administration (FDA) had a deferral period of 14 days post vaccination in case of live-attenuated viral vaccine or if the personis symptomatic. However, in individuals with a non-replicating, inactivated, or mRNA-based COVID-19 vaccine, blood donation is allowed without a waiting period. 10 In the United Kingdom (UK), vaccines currently licensed are not live.

No deferral period is applied after immunization with non-live vaccines. None of these regulations have a well-defined established safetynet. Hence, a precautionary measure ofdonating blood 14 to 28days post vaccine deferral period is recommended at mostplaces. 11 Once the safety of COVID-19 vaccine on blood transmission is established, healthy asymptomatic individuals can donate blood more frequently with less deferral rates. This is important to prevent acute deficit due to surge in COVID-19 cases leading to drop in storage products.

Implications of reduced blood and its products will prove catastrophic, endangering a cohort of patients, if not dealt with timely. Maternal complications, major surgeries, hemorrhage, severe anemia, and a plethora of blood dyscrasias such as leukemia and sickle cell anemia among others, all necessitate the urgent requirement of blood and its components. 12 Availability of blood has been one of the main reasons for reducing the rates of maternal mortality. 13 It is therefore imperative that there are at least minimum adequate blood reserves to deal with life threatening situations. Selective blood banks and hospitals could be subjected to further strain as a result of outbreaks due to other diseases. Due to a surge in the COVID-19 cases and as a consequence of reduced blood supplies, several centers have also resorted to minimizing, postponing, or canceling electively scheduled operations, endoscopies, or other invasive procedures. In the future as hospitals eventually resume elective surgery, they will most likely encounter substantial number of surgical admissions, leading to long-term shortages which will probably persist even after the conclusion of the pandemic. 14 Besides an acute shortage of blood supplies, there also exists a dearth of testing agents and consumables as the laboratories are burdened with COVID-19

RT-PCR samples. 15 

Several strategies could possibly be employed to prevent an acute shortage. Prioritizing policies and contingency planning would lay the framework for effective management of blood and its products.

Blood donation, an essential service should be regarded as a permissible activity even during lockdown throughout the country. Theoverall deferral period after SARS-CoV-2 vaccination can possibly be reduced with strict hemovigilance systems to monitor potential causes of transfusion transmission. 7 Shortage of inventory supplies could be prevented by conducting regular updates of the available stock closely, and by monitoring activities that require increased use of available inventory such as elective surgeries. 16 During the pandemic, individuals seeking prior appointments for blood donation should be encouraged while walk-ins dissuaded. 17 In times of uncertainty, a few procedures and criteria with regards to donor safety could be considered for relaxation depending on the demand. For an instance, physical distribution of the certificate of appreciation could be replaced virtually.An attempt to increase the number of blood drives, can also help provide a short-term buffer in cases of immediate requirement in the early future. 18

It is also of utmost priority to strictly adhere to public health recommendations during the pandemic.

Guidelines for COVID-19 signs and symptoms should be disseminated among the masses with proper screening, monitoring and epidemiological surveillance. 19 In cases of essential workers being tested positive for SARS-CoV-2, contingency planning for staff replacement (reassignment and training of other non-essential staff), as well as strengthening psychological support of affected as well as for new personnel will prove beneficial. 20

On a concluding note, thecrisis of blood shortage amidst the ongoing pandemicneeds a collaborative effort from the various stakeholders ranging from blood donors, community health workers, blood transfusion services, and administration in order to protect and save more lives.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

All the authors contributed equally for study concept or design, data collection, data analysis or interpretation and writing the paper.

Effects of the COVID-19 pandemic on supply and use of blood for transfusion

Maintaining a safe and adequate blood supply and collecting convalescent plasma in the context of the COVID-19 pandemic

Blood supply management in times of SARS-CoV-2 pandemic -challenges, strategies adopted, and the lessons learned from the experience of a hospitalbased blood centre

WHO. Global Status Report on Blood Safety and Availability

Updated Information for Blood Establishments Regarding COVID-19

Blood shortage due to lack of blood donors during COVID-19 pandemic

Maternal mortality in sub-Saharan Africa: the contribution of ineffective blood transfusion services

Blood Banking and Transfusion Medicine Challenges During the COVID-19 Pandemic

Impact of COVID 19 pandemic on blood transfusion services at a rural based district Hospital Blood-Bank

Revisiting blood transfusion preparedness: experience from the Bam earthquake response. Prehospital and disaster medicine

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:

Unique Identifying number or registration ID:3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Utkarsha Uday J o u r n a l P r e -p r o o f